J
James M. Rini
Researcher at University of Toronto
Publications - 82
Citations - 9189
James M. Rini is an academic researcher from University of Toronto. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 39, co-authored 77 publications receiving 7882 citations. Previous affiliations of James M. Rini include Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
Galectins: a family of animal beta-galactoside-binding lectins.
Samuel H. Barondes,Vincent Castronovo,Douglas N.W. Cooper,Richard D. Cummings,Kurt Drickamer,Ten Felzi,Michael A. Gitt,Jun Hirabayashi,Colin Hughes,Ken-ichi Kasai,Hakon Leffler,Fu-Tong Liu,Reuben Lotan,Arthur M. Mercurio,Michel Monsigny,Shiv Pillai,Françoise Poirer,Avraham Raz,Peter W.J. Rigby,James M. Rini,John L. Wang +20 more
Journal ArticleDOI
Structural basis of calcium-induced E-cadherin rigidification and dimerization
Bhushan Nagar,Michael Overduin,Michael Overduin,Mitsuhiko Ikura,Mitsuhiko Ikura,James M. Rini +5 more
TL;DR: The E-cadherin dual-domain structure reported here defines the role played by calcium in the cadherin-mediated formation and maintenance of solid tissues.
Journal ArticleDOI
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
R. Brad Jones,Lishomwa C. Ndhlovu,Jason D. Barbour,Prameet M. Sheth,Aashish R. Jha,Brian Long,Jessica Wong,Malathy Satkunarajah,Marc Schweneker,Joan M. Chapman,Gabor Gyenes,Bahareh Vali,Martin D. Hyrcza,Feng Yun Yue,Colin Kovacs,Aref Sassi,Mona R. Loutfy,Roberta Halpenny,Desmond Persad,Gerald Spotts,Frederick Hecht,Tae-Wook Chun,Joseph M. McCune,Rupert Kaul,James M. Rini,Douglas F. Nixon,Mario A. Ostrowski +26 more
TL;DR: Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1–specific T cells and represents a novel target for the therapeutic reversal of HIV–1–associated T cell dysfunction.
Journal ArticleDOI
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
Baweleta Isho,Kento T. Abe,Kento T. Abe,Michelle Zuo,Alainna J Jamal,Alainna J Jamal,Bhavisha Rathod,Jenny Wang,Zhijie Li,Gary Chao,Olga L. Rojas,Yeo Myong Bang,Annie Pu,Natasha Christie-Holmes,Christian Gervais,Derek F. Ceccarelli,Payman Samavarchi-Tehrani,Furkan Guvenc,Patrick Budylowski,Angel Li,Aimee Paterson,Feng Yun Yue,Lina María Marín,Lauren Caldwell,Jeffrey L. Wrana,Jeffrey L. Wrana,Karen Colwill,Frank Sicheri,Frank Sicheri,Samira Mubareka,Scott D. Gray-Owen,Steven J. Drews,Walter L. Siqueira,Miriam Barrios-Rodiles,Mario A. Ostrowski,Mario A. Ostrowski,James M. Rini,Yves Durocher,Allison McGeer,Allison McGeer,Allison McGeer,Jennifer L. Gommerman,Anne-Claude Gingras,Anne-Claude Gingras +43 more
TL;DR: It is confirmed that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in the majority of COVID-19 patients for at least 3 months PSO, and IgG responses in saliva may serve as a surrogate measure of systemic immunity to Sars-Cov-2 based on their correlation with serum IgG responds.
Journal ArticleDOI
Structural evidence for induced fit as a mechanism for antibody-antigen recognition
TL;DR: The structures of the free and antigen bound antibodies demonstrate the flexibility of the antibody combining site and provide an example of induced fit as a mechanism for antibody-antigen recognition.